A database of FDA approved therapeutic peptides and proteins
ID1059 | ThPPIDTh1010 | NameInterferon alfa-n1 | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseInfectious /Immunological | BrandWellferon | CompanyGlaxoSmithKline | Physical AppearanceSolution | Route of AdministartionInjection | CategoryAntiviral Agents, Immunologic factors, Immunosuppressiv agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1187 | ThPPIDTh1024 | NameGramicidin D | Peptide SequenceVGALAVVVWLWLWLWX Full view | Length16 | Functional ClassificationIIa | DiseaseInfectious | BrandNeosporin | CompanyPfizer | Physical AppearanceOintment | Route of AdministartionExternal use only | CategoryAnti-Bacterial Agents, Anti-infective, Topical, Antibiotic | TargetN.A. |
ID1188 | ThPPIDTh1024 | NameGramicidin D | Peptide SequenceVGALAVVVWLWLWLWX Full view | Length16 | Functional ClassificationIIa | DiseaseInfectious | BrandSofradex | CompanySanofi | Physical AppearanceSterile, clear, bright, colourless, aqueous solution | Route of AdministartionAuricular and Ocular use. | CategoryAnti-Bacterial Agents, Anti-infective, Topical, Antibiotic | TargetN.A. |
ID1257 | ThPPIDTh1036 | NameAldesleukin | Peptide SequenceMAPTSSSTKKTQLQLEHLLL Full view | Length134 | Functional ClassificationIb | DiseaseCancer/Infectious | BrandProleukin | CompanyChiron Corp | Physical AppearanceSterile, white to off-white, lyophilized cake | Route of AdministartionIntravenous administration | CategoryAntineoplastic Agents, Anti-HIV agents | TargetInterleukin-2 receptor subunit beta,Interleukin-2 receptor subunit alpha,Cytokine receptor common subunit gamma |
ID1341 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandAvonex | CompanyBiogen Inc | Physical AppearanceLyophilized powder vial, Sterile liquid as single used prefilled syringe and also available as single use prefilled autoinjector. | Route of AdministartionIntramuscular Injection | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1342 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandBetaferon | CompanyBayer | Physical AppearancePowder and solvent that are made upto make solution. | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1343 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandBetaseron | CompanyMerck | Physical AppearanceSterile, white to off-white powder | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1344 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandBlastoferon | CompanySidus | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1345 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandExtavia | CompanyNovartis | Physical AppearanceSterile, white to off-white powder | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1346 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandRebif | CompanyMerck | Physical AppearanceSterile solution in a prefilled syringe or REBIF Rebidose autoinjector | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1379 | ThPPIDTh1058 | NameInterferon alfacon-1 | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseImmunological/Infectious | BrandINFERGEN | CompanyKadmon Pharmaceuticals, LLC. | Physical AppearanceSterile, clear, colorless, preservative-free liquid | Route of AdministartionSubcutaneous Injection | CategoryAntiviral Agents and Immunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1409 | ThPPIDTh1067 | NameDaptomycin | Peptide SequenceN.A. Full view | Length0 | Functional ClassificationIIa | DiseaseInfectious | BrandCUBICIN | CompanyCubist Pharmaceuticals, Inc | Physical AppearanceSterile, preservative-free, pale yellow to light brown, lyophilized cake containing approx 500 mg of daptomycin | Route of AdministartionIntravenous(IV) Injection | CategoryN.A. | TargetB-lymphocyte antigen CD20,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,Complement C1s subcomponent,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
ID1462 | ThPPIDTh1088 | NameEnfuvirtide | Peptide SequenceYTSLIHSLIEESQNQQEKNE Full view | Length36 | Functional ClassificationIIa | DiseaseInfectious | Brand`FUZEON | CompanyTrimeris, Roche | Physical AppearanceWhite to off-white, sterile, lyophilized powder. | Route of AdministartionSubcutaneous injection | CategoryHIV Fusion Inhibitors | TargetOxytocin receptor,Oxytocin-neurophysin 1, Envelope glycoprotein |
ID1465 | ThPPIDTh1089 | NamePalivizumab | Peptide SequenceVH region: QVTLRESG< Full view | Length120 | Functional ClassificationIIIa | DiseaseInfectious | BrandSynagis | CompanyMedImmune | Physical AppearanceSterile, preservative-free liquid solution | Route of AdministartionIntramuscular injection | CategoryAntiviral Agents | TargetN.A. |
ID1531 | ThPPIDTh1110 | NameThymalfasin | Peptide SequenceSDAAVDTSSEITTKDLKEKK Full view | Length28 | Functional ClassificationIb | DiseaseInfectious/Immunological | BrandZadaxin | CompanySciClone Pharmaceuticals (SCLN) | Physical AppearanceN.A. | Route of AdministartionSubcutaneous injection | CategoryN.A. | TargetN.A. |
ID1533 | ThPPIDTh1112 | NameNatural Alpha Interferon Or Multiferon | Peptide SequenceInteferon alpha-1: Full view | Length997 | Functional ClassificationIIa | DiseaseCancer/Infectious | BrandIntron/ Roferon-A | CompanyN.A. | Physical AppearanceN.A. | Route of AdministartionSubcutaneous injection, Intravenous injection, Intramuscular injection | CategoryN.A. | TargetN.A. |
ID1536 | ThPPIDTh1115 | NameTeicoplanin | Peptide SequenceN.A. Full view | Length0 | Functional ClassificationIIa | DiseaseInfectious | BrandTargocid | CompanyNPS Pharmaceuticals | Physical AppearanceLight yellow solid | Route of AdministartionIntravenous injection, Intramuscular injection | CategoryAnti-Bacterial Agents | TargetD-Ala-D-Ala moiety of NAM/NAG peptide subunits of peptidoglycan |
ID1627 | ThPPIDTh1138 | NameRaxibacumab | Peptide SequenceN.A. Full view | Length0 | Functional ClassificationIIa | DiseaseImmunological/Infectious | BrandRAXIBACUMAB | CompanyGSK | Physical AppearanceSterile, liquid formulation in single-dose vials | Route of AdministartionN.A. | CategoryAnti-Infective Agents and Monoclonal antibodies | TargetProtective antigen |
ID1659 | ThPPIDTh1152 | NameDrotrecogin alfa | Peptide SequenceHeavy Chain: LIDGKMT Full view | Length402 | Functional ClassificationIb | DiseaseInfectious | BrandXigris | CompanyEli Lilly and Company | Physical AppearanceSterile, lyophilized, white to off-white powder | Route of AdministartionIntravenous Infusion | CategoryAntisepsis | TargetCoagulation factor VIII, V, Plasminogen activator inhibitor 1, Thrombomodulin, Vitamin K-dependent protein S, Ceruloplasmin, Prothrombin, Platelet factor 4, Plasma serine protease inhibitor, Serpin B6, Vitamin K-dependent gamma-carboxylase, Endothelial protein C receptor |
ID1662 | ThPPIDTh1154 | NameOspA lipoprotein | Peptide SequenceMKKYLLGIGLILALIACKQN Full view | Length272 | Functional ClassificationIIIa | DiseaseInfectious | BrandLymerix | CompanySmithKline Beecham | Physical AppearanceSterile suspension | Route of AdministartionIntramuscular Injection | CategoryVaccines | TargetToll-like receptor 2 |
ID1758 | ThPPIDTh1183 | NameHepatitis B immune globulin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIa | DiseaseInfectious Disease | BrandHepagam B | CompanyCangene Bio Pharma Inc. | Physical AppearanceInjection, Solution | Route of AdministartionIntramuscular; Intravenous | CategoryNA | TargetHBsAg |
ID1762 | ThPPIDTh1183 | NameHepatitis B immune globulin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIa | DiseaseInfectious Disease | BrandHyperhep B S/d | CompanyGRIFOLS USA, LLC | Physical AppearanceInjection | Route of AdministartionIntramuscular | CategoryNA | TargetHBsAg |
ID1763 | ThPPIDTh1183 | NameHepatitis B immune globulin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIa | DiseaseInfectious Disease | BrandNabi-HB | CompanyBiotest Pharmaceuticals Corporation | Physical AppearanceInjection | Route of AdministartionIntramuscular | CategoryNA | TargetHBsAg |
ID1767 | ThPPIDTh1185 | NameHuman clostridium tetani toxoid immune globulin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIb | DiseaseInfectious Disease | BrandHypertet S/d | CompanyGRIFOLS USA, LLC | Physical AppearanceInjection | Route of AdministartionIntramuscular | CategoryNA | TargetNA |
ID1768 | ThPPIDTh1186 | NameHuman rabies virus immune globulin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIa | DiseaseInfectious Disease | BrandHyperab Rabies Immune Globulin Human | CompanyCutter Med & Biol, Division Of Miles Canada Ltd. | Physical AppearanceLiquid | Route of AdministartionIntramuscular | CategoryNA | TargetNA |
ID1769 | ThPPIDTh1186 | NameHuman rabies virus immune globulin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIa | DiseaseInfectious Disease | BrandHyperrab S/d | CompanyGrifols Therapeutics Inc | Physical AppearanceSolution | Route of AdministartionIntramuscular | CategoryNA | TargetNA |
ID1770 | ThPPIDTh1186 | NameHuman rabies virus immune globulin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIa | DiseaseInfectious Disease | BrandImogam Rabies Inj 150unit/ml | CompanyPasteur mÉrieux Serums Et Vaccins, s.a. | Physical AppearanceClear, pale yellow to light brown liquid | Route of AdministartionIntramuscular | CategoryNA | TargetNA |
ID1771 | ThPPIDTh1186 | NameHuman rabies virus immune globulin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIa | DiseaseInfectious Disease | BrandImogam Rabies Pasteurized | CompanySanofi Pasteur Limited | Physical AppearanceSolution | Route of AdministartionIntramuscular | CategoryNA | TargetNA |
ID1798 | ThPPIDTh1192 | NameUstekinumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIb | DiseaseInfectious Disease | BrandStelara | CompanyJanssen Biotech, Inc. | Physical AppearanceSolution fro Injection | Route of AdministartionSubcutaneous | CategoryDeramtologic agent, Immunosuppressive agent, antineoplastic agent | TargetInterleukin-12 subunit beta |
ID1800 | ThPPIDTh1194 | NameTuberculin Purified Protein Derivative | Peptide SequenceNA Full view | Length0 | Functional ClassificationIV | DiseaseInfectious Disease | BrandAplisol | CompanyPar Pharmaceutical, Inc. | Physical AppearanceSolution for Injection | Route of AdministartionIntradermal | CategoryNA | TargetNA |
ID1814 | ThPPIDTh1205 | NameObiltoxaximab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIa | DiseaseInfectious Disease | BrandAnthim | CompanyElusys Therapeutics, Inc. | Physical AppearanceLiquid | Route of AdministartionIntravenous infusion | CategoryNA | TargetNA |
ID1820 | ThPPIDTh1211 | NameIxekizumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIc | DiseaseInfectious Disease | BrandTaltz | CompanyEli lilly | Physical AppearanceSterile, preservative free, clear and colorless to slightly yellow Solution | Route of AdministartionSubcutaneous | CategoryNA | TargetNA |
ID1840 | ThPPIDTh1229 | NameHepatitis A Vaccine | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIa | DiseaseInfectious Disease | BrandAvaxim | CompanySanofi Pasteur Limited | Physical AppearanceSuspension | Route of AdministartionIntramuscular | CategoryVaccine | TargetNA |
ID1841 | ThPPIDTh1229 | NameHepatitis A Vaccine | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIa | DiseaseInfectious Disease | BrandHavrix | CompanyDispensing Solutions, Inc. | Physical AppearanceSuspension | Route of AdministartionIntramuscular | CategoryVaccine | TargetNA |
ID1842 | ThPPIDTh1230 | NameHuman Varicella-Zoster Immune Globulin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIIIa | DiseaseInfectious Disease | BrandVARIZIG | CompanyNA | Physical Appearancelyophilized powder for solution | Route of AdministartionIntramuscular | CategoryAntibody | Targetvaricella zoster virus |